Edward Nash

Stock Analyst at Canaccord Genuity

(4.06)
# 568
Out of 5,042 analysts
79
Total ratings
54.93%
Success rate
12.37%
Average return

Stocks Rated by Edward Nash

Akero Therapeutics
Oct 9, 2025
Downgrades: Hold
Price Target: $73$54
Current: $53.77
Upside: +0.43%
Sagimet Biosciences
Oct 2, 2025
Maintains: Buy
Price Target: $28
Current: $9.14
Upside: +206.35%
Inventiva
Sep 30, 2025
Maintains: Buy
Price Target: $20
Current: $6.20
Upside: +222.58%
Corcept Therapeutics
Sep 25, 2025
Maintains: Buy
Price Target: $140
Current: $72.52
Upside: +93.05%
Celldex Therapeutics
Sep 17, 2025
Maintains: Buy
Price Target: $62
Current: $26.72
Upside: +132.04%
Madrigal Pharmaceuticals
Sep 12, 2025
Maintains: Buy
Price Target: $428$526
Current: $421.50
Upside: +24.79%
Travere Therapeutics
Apr 10, 2025
Maintains: Buy
Price Target: $45$47
Current: $28.06
Upside: +67.50%
Rani Therapeutics Holdings
Feb 26, 2025
Maintains: Buy
Price Target: $9
Current: $1.82
Upside: +394.51%
Pliant Therapeutics
Feb 10, 2025
Downgrades: Hold
Price Target: $4
Current: $1.81
Upside: +120.99%
Apogee Therapeutics
Nov 25, 2024
Initiates: Buy
Price Target: $89
Current: $53.32
Upside: +66.92%
Maintains: Buy
Price Target: $15$14
Current: $5.81
Upside: +140.96%
Maintains: Buy
Price Target: $6$8
Current: $1.19
Upside: +572.27%
Maintains: Buy
Price Target: $16$17
Current: $9.19
Upside: +84.98%
Maintains: Hold
Price Target: $3$2
Current: $2.39
Upside: -16.32%
Downgrades: Hold
Price Target: $900$180
Current: $1.38
Upside: +12,943.48%
Maintains: Buy
Price Target: $80$82
Current: $33.53
Upside: +144.56%
Maintains: Hold
Price Target: $120$80
Current: $4.07
Upside: +1,865.60%
Initiates: Buy
Price Target: $48
Current: $61.01
Upside: -21.32%
Initiates: Buy
Price Target: $650
Current: $5.48
Upside: +11,761.31%